References:
1. Buse DC, Manack AN, Fanning KM et al. Chronic migraine prevalence,
disability, and sociodemographic factors: results from the American
Migraine Prevalence and Prevention Study. Headache: The Journal of
Head and Face Pain . 2012;52:1456-70.
2. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine.Headache . 2006;46 Suppl 1(Suppl 1):S3-S8.
3. Edvinsson L, Haanes KA, Warfvinge K et al. CGRP as the target of new
migraine therapies—successful translation from bench to clinic.Nature Reviews Neurology . 2018;14:338-50.
4. Evans RW. Raynaud’s Phenomenon Associated With Calcitonin
Gene-Related Peptide Monoclonal Antibody Antagonists. Headache .
2019;59:1360-4.
5. Durham PL. CGRP-receptor antagonists—a fresh approach to migraine
therapy? New England Journal of Medicine . 2004;350:1073-5.